In the following video, Motley Fool health-care analyst David Williamson highlights a potential new threat to an entire class of multibillion-dollar drugs. The drug group, which treats type 2 diabetes, could be linked to pancreatitis, a very serious inflammation of the pancreas that can lead to pancreatic cancer. David tells investors how several companies, such as Merck (MRK -0.12%), Bristol-Myers Squibb (BMY -1.27%) and AstraZeneca (AZN -0.93%) could be affected if the link is confirmed, and how serious the damage could be financially.